Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer

ConferenceAVA6103Positive

AI Analysis

Summary

Avacta Group announced the presentation of FOCUS-01 Phase 1 trial design and preclinical data for AVA6103 (FAP-Exd) in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic Cancer in San Diego, September 25-28, 2026.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Presentation of FOCUS-01 trial design and preclinical data at AACR Conference on Pancreatic Cancer

Importance:5/10

Sentiment:

0.50

oncologypeptide-drug conjugatepancreatic cancerclinical trialconference presentation

Related Companies

$AVCT

Read the original article

Published by GlobeNewswire Clinical Studies on September 25, 2026 6:00 AM

Read Original